Geron Corporation (GERN) Eyes Profitability in 2026 amid Restructuring Drive

Geron Corporation (NASDAQ:GERN) is one of the champion debt-free penny stocks to bargain close now. On January 12, Geron Corporation (NASDAQ:GERN) announced its 2026 outlook, forecasting $220–240 cardinal successful RYTELO (imetelstat) gross and $230–240 cardinal successful operating expenses pursuing a caller restructuring. The blood-cancer-focused institution expects stronger maturation successful the 2nd fractional of the twelvemonth arsenic it increases outreach to physicians and patients.

Geron is prioritizing U.S. commercialization, planetary expansion, and advancement successful its Phase 3 IMpactMF trial. RYTELO, a first-in-class telomerase inhibitor approved successful the U.S. and EU for lower-risk MDS-related anemia, continues to physique objective support, with caller IMerge information presented astatine the 2025 ASH meeting. The institution besides amended its indebtedness statement with Pharmakon Advisors, securing entree to up to $125 cardinal done July 2026.

On December 16, the institution embarked connected a restructuring thrust to execute profitability successful the 2nd fractional of 2026. The institution is successful the process of trimming its workforce by astir a third, a determination expected to trim operating expenses. However, it is besides apt to effect successful an $18 cardinal successful restructuring charges associated with severance payments and healthcare benefits.

In summation to outgo cuts, the institution plans to absorption connected expanding its US commercialized income portion pursuing planetary opportunities successful Europe for its cardinal products.

“Our cardinal objectives stay unchanged. We are focused connected driving RYTELO commercialized maturation successful the U.S., exploring opportunities for making RYTELO disposable extracurricular the U.S., and continuing to beforehand our Phase 3 IMpactMF trial. We expect this restructuring volition person a meaningful interaction connected our 2026 operating expenses and presumption Geron to conscionable the needs of patients,” said Harout Semerjian, President and Chief Executive Officer of Geron.

Geron Corporation (NASDAQ:GERN) is simply a commercial-stage biopharmaceutical institution focused connected processing and selling treatments for humor cancers, chiefly utilizing its first-in-class telomerase inhibitor, RYTELO (imetelstat). RYTELO is approved successful the U.S. and EU for definite patients with lower-risk myelodysplastic syndromes (MDS).

While we admit the imaginable of GERN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Blue Chip Stocks to Buy for 2026 and 10 Best Metal Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.